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Abstract
Manganese (Mn) is an essential heavy metal. However, Mn’s nutritional aspects are paralleled by its role as a
neurotoxicant upon excessive exposure. In this review, we covered recent advances in identifying mechanisms of
Mn uptake and its molecular actions in the brain as well as promising neuroprotective strategies. The authors
focused on reporting findings regarding Mn transport mechanisms, Mn effects on cholinergic system, behavioral
alterations induced by Mn exposure and studies of neuroprotective strategies against Mn intoxication. We report
that exposure to Mn may arise from environmental sources, occupational settings, food, total parenteral nutrition
(TPN), methcathinone drug abuse or even genetic factors, such as mutation in the transporter SLC30A10.
Accumulation of Mn occurs mainly in the basal ganglia and leads to a syndrome called manganism, whose
symptoms of cognitive dysfunction and motor impairment resemble Parkinson’s disease (PD). Various
neurotransmitter systems may be impaired due to Mn, especially dopaminergic, but also cholinergic and
GABAergic. Several proteins have been identified to transport Mn, including divalent metal tranporter-1 (DMT-1),
SLC30A10, transferrin and ferroportin and allow its accumulation in the central nervous system. Parallel to
identification of Mn neurotoxic properties, neuroprotective strategies have been reported, and these include
endogenous antioxidants (for instance, vitamin E), plant extracts (complex mixtures containing polyphenols and
non-characterized components), iron chelating agents, precursors of glutathione (GSH), and synthetic compounds
that can experimentally afford protection against Mn-induced neurotoxicity.
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Background
Manganese (Mn) is a naturally occurring heavy metal
present as the fifth most abundant metal in the environ-
ment and twelfth most abundant element as a whole. Mn
is essential for humans and animals and daily require-
ments are commonly met by an adequate diet. Legumes,
rice, nuts and whole grains contain the highest levels of
the metal. Mn is also found in seafood, seeds, chocolate,
tea, leafy green vegetables, spices, soybean, and some
fruits such as pineapple and acai. An overview of Mn con-
tent in common Mn-rich foods can be found in Table 1.
The recommended daily intake of Mn for adult men is 2.3
and 1.8 mg/day for adult women [1]. For children, these
values vary with age and are shown in Table 2. For ages 0
to 6 months the Institute of Medicine’s Dietary Reference
Intake for Mn cites an adequate intake (AI) that reflects
the observed mean Mn intake from human milk. In an
earlier study, total Mn secretion in human milk was
estimated to be 1.9 μg/day over the first 3 months and
1.6 μg/day over the second 3 months [2]. Based on these
values, the AI is set according to average milk volume
consumption (0.78 L/day). At ages 7 to 12 months, with
the introduction of complementary foods, AI is increased.
For ages 1 through 18 years, the AI is based on median Mn
intake data obtained from the Food and Drug Administra-
tion Total Diet Study. The Dietary Reference Intake also
lists 9–11 mg/day Mn as the upper tolerable limit likely to
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Table 1 An overview of manganese (Mn) content in food and drinks
Food Country of origin Mn content (±SD) Reference






Beef meat Xangai, China 0.848 ± 1.10 μg/g [214]






Chicken meat Xangai, China 0.561 ± 4.18 μg/g [214]
Chinese chive South Korea 1.17 ± 0.04 μg/g [216]




5.02 ± 0.52 μg/g
4.97 ± 0.10 μg/g
6.19 ± 0.02 μg/g
6.28 ± 1.01 μg/g
[217]
Duck meat Xangai, China 0.54 ± 0.23 μg/g [214]
Freshwater fish Xangai, China 0.47 to 0.96 μg/g [214]













Lemon Nigeria 0.23 ppm [213]
Lettuce Egypt 20.0 ± 1.0 μg/g [215]
Marine mussels
Mytilus edulis and Perna viridis
England, USA, Sweden, Scotland,
Canada, China.Hong Kong, China,
Malasya,
10 to 100 μg/g












0.0215 ± 0.01 or 0.0166 ± 0.01 ppm
3 to 10 μg/L
[220]
Mineral water Egypt 2.35 ± 0.16 ɳg/mL [215]
Onion Kosovo 0.002 to 1.29 μg/g [219]












Pork meat Xangai, China 0.602 ± 0.697 μg/g [214]
Potatoes
(white, red, orange-fleshed)
Canary Islands, Spain 2.71 ± 2.22, 2.57 ± 1.69,
1.74 ± 0.14 μg/g
[223]
Radish Kosovo 0.038 to 1.33 μg/g [219]
Rice Australia 24.4 μg/g [224]
River water Egypt 2.16 ± 0.16 ɳg/mL [215]
Seawater fish Xangai, China 0.437 to 0.953 μg/g [214]
Shellfish Xangai, China 0.437 to 18.15 μg/g [214]
Peres et al. BMC Pharmacology and Toxicology  (2016) 17:57 Page 2 of 20
pose no risk of adverse health effects for adults, and 2–
6 mg/day Mn for children, depending on the age. Only a
small percentage of these amounts are absorbed from the
intestine, since the gut tightly controls body Mn load and
the metal is rapidly and efficiently excreted via bile as long
as no hepatic disease takes place [3, 4].
The physiological concentration of Mn in the human
brain is estimated to lie between 5.32 and 14.03 ng Mn/mg
protein (20.0–52.8 μM Mn), whereas 15.96–42.09 ng Mn/
mg protein (60.1–158.4 μM Mn) is the estimated patho-
physiological threshold [5]. Mn is essential for several
physiological processes participating in enzymatic reactions
as a cofactor. Mn acts in gluconeogenesis as an activator of
pyruvate carboxylase and in the Krebs Cycle as a cofactor
for isocitrate dehydrogenase. In the antioxidant defense sys-
tem, Mn is part of superoxide dismutase (SOD). Moreover,
Mn is present in the central nervous system (CNS) as a
cofactor for glutamine synthetase (GS), which is preferen-
tially localized in astrocytes [6]. Mn deficiency is a rare con-
cern. Few reports of experimental Mn deficiency have cited
poor bone growth, skeletal abnormalities, ataxia, skin alter-
ations and hypocholesterolemia [4, 7].
Mn overload may arise from an impaired or not fully
developed excretion system, transporter malfunction or
exposure to excessive levels of Mn by air, water, food or
total parenteral nutrition (TPN). Given the similarities
between Mn and iron (Fe), homeostasis of both metals
is interdependent, thus the Fe status also influences Mn
accumulation. This is noted in cases of anemia, for ex-
ample, when low levels of Fe facilitate Mn uptake [8].
Occupational exposure is one of the main concerns for
Mn intoxication and it occurs in activities involving
mining, welding, battery manufacture and with the use
of fungicides containing the metal in its composition,
such as maneb and mancozeb [9–12]. Periods of occupa-
tional exposure of 6 months to 2 years may lead to the
development of manganism. The motor and neuro-
psychiatric symptoms may remain even 14 years after
the end of exposure to Mn [13].
The risk of Mn exposure is not limited to miners or
welders. The availability of the metal in the environment,
water or food containing high levels of Mn represents a
source of contamination for the general population [14].
Furthermore, the levels of Mn in the atmosphere may in-
crease secondary to the use of the gasoline additive
methylcyclopentadienyl manganese tricarbonyl (MMT)
[15]. Drug abuse has recently become a concern for Mn
poisoning, since abusers of the injectable drug methcathi-
none may be exposed to contaminating Mn due to the use
Table 1 An overview of manganese (Mn) content in food and drinks (Continued)
Soybean





18.2 to 44.3 μg/g






24.60 ± 1.10 μg/g
0.006 to 1.25 μg/g









Tap water Egypt 1.74 ± 0.10 ɳg/mL [215]






White bread Egypt 3.20 ± 0.36 μg/g [215]
Wild chive South Korea 3.06 ± 0.04 μg/g [216]
Wild parsley South Korea 3.45 ± 0.05 μg/g [216]
Wine Greece 2.2 to 10 mg/L [228]
Content expressed as interval, standard deviation (SD) or parts per million (ppm)
Table 2 Summary of Mn adequate intake ages 0 through 18 years
Gender Age group AI (mg/day of Mn)




Girls 9–13 years 1.6
14–18 years 1.6
Boys 9–13 years 1.9
14–18 years 2.2
Source: Institute of Medicine’s Dietary Reference Intake for Mn
Abbreviations: AI adequate intake
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of potassium permanganate in the synthesis process [16].
Patients with hepatic impairment and those receiving
TPN, especially newborns, are susceptible to Mn accumula-
tion [9, 17–19]. Infants and children are particularly vulner-
able to inappropriate supplementation of Mn, which in
some cases may lead to hypermanganesemia, dependent
upon the duration of the treatment [17, 18, 20, 21].
Additionally, Mn is present at levels considered excessive in
children’s formula [17].
Mutations in the SLC30A10 gene have been reported to
induce a genetic Mn overload syndrome. SLC30A10 is a
Mn transporter and a recessive loss-of-function mutation
in its gene causes a syndrome of movement disorder and
chronic liver disease. Magnetic resonance imaging (MRI)
of patients with this mutation shows Mn accumulation in
the basal ganglia and white matter, even in the absence of
previous exposure to high Mn levels [3, 22, 23].
The central nervous system (CNS) is the main target of
Mn. Excess Mn preferentially accumulates in the basal gan-
glia, especially in the striatum (caudate nucleus, putamen
and nucleus accumbens), globus pallidus (GP) and the sub-
stantia nigra (SN) [24, 25]. Recently, the SN pars compacta
(SNpc) was identified as a site of Mn accumulation in rats
exposed intraperitoneally (ip) [26]. The neurodegenerative
process induced by accumulation of Mn is called mangan-
ism. Manganism is a syndrome similar to Parkinson’s disease
(PD), characterized by psychiatric and cognitive deficits and
motor impairment [27, 28]. Mn is also a putative environ-
mental modifier of Huntington’s disease (HD) [29–31]. The
symptoms caused by the accumulation of Mn include dys-
tonia, bradykinesia and rigidity due to damage to dopamin-
ergic (DAergic) neurons and gliosis [12, 32]. Manganism
and PD affect different areas of the brain, which allowing for
a distinction between the two syndromes. SNpc DAergic
neurons are progressively lost in PD, whereas the GP is pre-
dominantly affected in manganism. Lewy bodies formation
is a hallmark of PD, which is not observed in manganism. In
addition, manganism is not responsive to treatment with
DA precursor levodopa, a drug used in the early stages of
PD. Furthermore, manganism presents with a lack of resting
tremor but consistent presence of dystonia [33–35].
Mn exposure alters intracellular signaling pathways in
mouse and rat striatum, as well as cell culture models.
These include alterations in Akt, ERK, p38, DARPP-32
and tyrosine hydroxylase (TH) phosphorylation [36–42].
Transcription factors’ localization, such as NF-κB and
NF-E2-related factor 2 (Nrf2), is affected [43, 44]. Of
particular interest, Mn-induced p53 phosphorylation, as
well as upregulation of p53 levels, have been shown to
be important events in cellular response to Mn exposure
both in vivo and in vitro, possibly contributing to neur-
onal apoptosis [31, 45–47]. Endoplasmic reticulum (ER)
stress is another factor that may lead to Mn-induced
apoptosis [48].
A proper balance of Mn levels is essential for mainten-
ance of health and avoidance of neurotoxicity. It is thus
imperative to study the regulatory mechanisms of Mn
uptake as well as its molecular mechanism of toxicity.
The main topics of this review will focus on Mn effects
in the brain, especially mechanisms of Mn transport and
disruption of neurotransmitter signaling. We will discuss
the behavioral aspects of Mn intoxication and possible
neuroprotective strategies.
Main text
Mechanisms of Mn uptake into the CNS
As Mn is required for multiple cellular events but
becomes toxic at high levels, the intracellular Mn con-
centration has to be under strict control. Several mecha-
nisms regulate Mn homeostasis in the CNS, which
mainly relies on different Mn transporters. Given the
similar physical properties of Fe and Mn, most trans-
porters are able to transport both metals, which compete
for binding at the plasma membrane. To date, no pro-
teins are identified as Mn-specific transporters. The
brain is protected by the blood-brain barrier (BBB) and
there are primarily two ways for Mn to cross the BBB
and reach the brain for its function, discussed below.
Membrane localized Mn importers
Membrane importers are the primary route of Mn trans-
port into the CNS. These transporters include the
divalent metal transporter 1 (DMT1), Zrt-like, Irt-like
proteins ZIP8 (SLC39A8) and ZIP14 (SLC39A14),
dopamine transporter (DAT), voltage-regulated, store-
operated and ionotropic glutamate receptor Ca channels,
choline transporters and the citrate transporter [49, 50].
These proteins are localized on cell membranes and are
able to form a membrane pore to take up divalent Mn
from the extracellular matrix. Moreover, Mn may block
transient receptor potential channel (TRPC3), a
receptor-operated plasma membrane channel of astro-
cytes that responds to ATP-induced Ca signaling, thus
decreasing purinergic signaling [51].
DMT1 is the most representative and best studied
one. It is also known as divalent cation transporter 1
(DCT1), natural resistance-associated macrophage pro-
tein 2 (NRAMP 2) or solute carrier family 11 member 2
(SLC11A2). Gunshin et al. (1997), first cloned and char-
acterized DMT1 with a wide range of substrates, includ-
ing Fe2+, Zn2+, Mn2+, Cu2+, Co2+, Cd2+, Ni2+ and Pb2+
[52]. Garrick et al. (2006), showed that Mn is DMT1
preferred substrate, with the following transport affinity
(reflecting transport efficacy): Mn > Cd > Fe > Pb ~ Co ~
Ni > Zn [53]. Thus, although Fe has also been linked to
PD pathology, Mn might play a more prominent role in
this disease given its higher affinity for DMT1. In the
brain, DMT1 is highly expressed in the basal ganglia,
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including SN, GP, hypothalamic nucleus and striatum
[54–56], rendering these regions more susceptible to Mn
accumulation and toxicity. DMT1 regulates Mn influx
into neurons by two ways. One is via a direct transport
mechanism whereby the membrane-localized DMT1
opens up a pore and allows the extracellular divalent
Mn to enter neurons. The other way is via a transferrin
(Tf)-dependent process, which will be discussed next.
Transferrin (Tf) and transferrin receptor (TfR)
While the majority of Mn in the body is in the divalent
oxidation state, there is a small amount of trivalent Mn,
which is not a substrate for the above referenced im-
porters. Tf/TfR facilitates Mn3+ influx into the CNS from
the blood stream [57]. Tf is synthesized in the liver and
then released into the blood [58]. Mn exposure increases
the expression of TfR by enhancing the binding of iron
regulatory proteins (IRPs) to iron responsive element-
containing RNA in vitro [59]. TfR is a membrane protein
with high affinity for Mn, which is expressed in neurons,
microglia, astrocytes and the endothelial cells of the BBB
[60]. When TfR recognizes and binds to Tf, the cell
membrane expands inwardly and forms an endocytic
vesicle, which brings in the Mn [67, 74]. Mn3+ is a stron-
ger oxidizing agent than Mn2+ and it may cause severe
oxidative stress. Ferrireductase reduces Mn3+ into Mn2+,
which is released into the cytosol by DMT1 localized on
the endosomal membrane [50].
Mn export in the CNS
Efflux plays a fundamental role in regulating intracellular
concentrations of Mn in the CNS. Compared with Mn im-
port, efflux of Mn is less studied, partially due to limited
proteins identified in Mn export. However, with the recent
discovery of four proteins facilitating Mn export, the role
of Mn export has begun to be elucidated. These four pro-
teins include ferroportin (Fpn), SLC30A10 (solute carrier
family 30 member 10), secretory pathway Ca2+-ATPase 1
(SPCA1) and ATPase 13A2 (ATP13A2 or PARK9).
Among them, Fpn and SLC30A10 are able to directly ex-
port cytosolic Mn out of neurons, while SPCA1 and
ATP13A2 indirectly regulate Mn efflux through the Golgi
apparatus and lysosome, respectively. Together, these pro-
teins maintain Mn homeostasis in the CNS and mutations
in them have been associated with certain diseases.
Membrane localized Mn exporters
Currently, these exporters include Fpn and SCL30A10.
Fpn was the first known Mn exporter, however, it was
first identified as a Fe exporter. And that is why it is also
known as iron-regulated transporter 1 or solute carrier
family 40 member 1 (SLC40A1). In the brain, Fpn has
been found in neurons, astrocytes, the endothelial cells
of the BBB, oligodendrocytes, the choroid plexus and
ependymal cells [61]. Fpn expression levels are increased
in mice and human embryonic kidney cells in the
presence of Mn [62]. Xenopus laevis oocytes expressing
human Fpn showed lower intracellular Mn and higher
extracellular Mn [63]. Although these results indicate
Fpn may play an important role on Mn homeostasis in
the CNS, a direct study to investigate brain Mn levels in
human or animal models carrying Fpn mutations has
not been reported yet.
Interestingly, the recently identified SLC30A10 has
been well known to play a critical role in regulating CNS
Mn homeostasis. Currently, it is the only known protein
associated with the first hereditary or familial form of
Mn-induced parkinsonism. People carrying mutations in
SLC30A10 suffer from hypermanganesemia with dys-
tonia, polycythemia and hepatic cirrhosis [22, 64, 65].
The patients have ~10-fold increase in blood Mn levels
and magnetic resonance imaging (MRI) studies show
high levels of Mn accumulated in the basal ganglia
without a history of exposure to elevated Mn from
environmental or occupational sources [66]. The mecha-
nisms by which mutations in SLC30A10 mediate Mn ac-
cumulation were recently characterized in rat-derived
differentiated γ-aminobutyric acid (GABA) ergic AF5
cells, primary mice midbrain neurons and C. elegans.
Leyva-Illades, Chen et al. (2014), found that wild type
(WT) SLC30A10 is localized on the cell membrane,
while 5 mutant transporters are all trapped in the endo-
plasmic reticulum (ER) or in the cytoplasm [67]. While
the WT protein is able to protect from Mn induced
DAergic neurodegeneration and cell toxicity, the mislo-
calization deprives these mutants of this essential efflux
with ensuing retention of high Mn concentrations in the
plasma.
Mn efflux mediated by SPCA1 and ATP13A2
SPCA1 is a Golgi-localized Ca/Mn ion pump, which be-
longs to the P-type ATPase family, with highest expres-
sion in keratinocytes but also in other tissues including
liver and brain [68]. In HeLa cells, SPCA1 is required
for transport of Mn into the Golgi, followed by secretion
via exocytosis as a bona-fide Mn efflux pathway [69].
ATP13A2 (PARK9) is a transmembrane cation trans-
porting ATPase localized on the membrane of vacuoles
and lysosomes [67]. ATP13A2 has been associated with
early-onset parkinsonism and Kufor-Rakeb syndrome
[70–72]. In primary rat neurons, ATP13A2 levels were
increased in the presence of excess Mn, while expression
of wild-type ATP13A2 lowered intracellular Mn levels
and prevented Mn-induced neuronal death [73].
Despite the evidence in cell culture studies, the role of
SPCA1 and ATP13A2 in mediating Mn efflux in the
CNS remains unclear. MRI studies to investigate Mn ac-
cumulation in the brain of patients or animal models
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carrying mutations in SPCA1 or ATP13A2 are needed
to validate the results from the cell culture studies. The
most studied Mn importers and exporters are summa-
rized in Table 3.
Recently, a high throughput screening approach was
carried out to identify small molecules responsible for
intracellular regulation of Mn homeostasis at physiolo-
gically relevant levels. It’s suggested that intracellular
Mn levels are actively controlled by the cell and not ex-
clusively by the BBB or blood-cerebrospinal fluid barrier.
Furthermore, mechanisms regulating Mn content might
be developmentally regulated in DAergic neurons
reflecting the changing physiological demand [74].
Mn and the cholinergic system
Mn-induced alterations in behavioral patterns, namely
motor incoordination or emotional and cognitive dysfunc-
tion, which observed in both patients and/or animal models,
are associated with neurotransmitter metabolism disruption.
Impaired neurotransmitter signaling may occur via diverse
mechanisms, such as neurotransmitter release inhibition, al-
terations in neurotransmitter clearance from the synaptic
cleft, or modulation of receptor levels or activity. The main
neurotransmitter system studied in Mn neurotoxicity is the
dopaminergic (DAergic) system [24, 75]; several studies have
also described Mn’s effects on the GABAergic [76] and glu-
tamatergic systems [77–82].
Mn at neurotoxic levels also affects the cholinergic sys-
tem. Acetylcholine (ACh) is an important excitatory
neurotransmitter both in the central and peripheral ner-
vous system, modulating essential cognitive functions,
such as learning, memory and locomotion. Given the scar-
city of attention devoted to this system, we will focus next
on Mn’s effects and cholinergic dysfunction [83–86].
The cholinergic system encompasses the neurotransmit-
ter ACh, the enzyme that synthesizes ACh named Choline
Acetyltransferase (ChaT; E.C. 2.3.1.6), the enzymes that
hydrolyze ACh called cholinesterases (acetylcholinester-
ase-AChE; E.C. 3.1.1.7 and butyrylcholinesterase-BuChE;
E.C. 3.1.1.8), by the cholinergic receptors (muscarinic and
nicotinic) and by the system that reuptakes choline. Dys-
function of the cholinergic system is associated with sev-
eral diseases, such as Alzheimer’s disease (AD) and
myasthenia gravis. Mn effects on the cholinergic system
may contribute to impairments in learning, memory and
locomotion [87]. Although several symptoms of PD and
manganism are largely related to effects on the DAergic
system, studies suggest that the cholinergic system might
play an important role in such diseases [83, 87]. Further-
more, Mn’s toxic effects might be related to an imbalance
between the DAergic and cholinergic systems, predomin-
antly in the basal ganglia [83].
ChAT is a marker of cholinergic function. A decrease
in its activity leads to diminished storage and release of
ACh affecting directly its function. Several reports have
addressed the ability of Mn to alter ChAT activity. Nu-
merous factors may contribute to this effect, including
the age of the animals and the duration of treatment,
since cholinergic neurons are exquisitely vulnerable in
the developing brains [83, 84].
AChE is an important regulatory enzyme that rapidly
hydrolyzes ACh at brain cholinergic synapses as well as
at the neuromuscular junction [88, 89]. AChE possesses
unique characteristics not found in any other enzyme, such
as its active site organization and its catalytic mechanism
[90–92]. AChE is extremely important in regulating brain
function, development, neurite outgrowth, neuronal sur-
vival, and calcium levels [83, 93]. Various toxicological con-
ditions that generate oxidative stress alter AChE activity,
mainly its membrane bound form. Such changes in activity
are commonly accompanied by clear signs of neurobehav-
ioral alterations [83, 94, 95]. For example, an increase in the
enzyme activity was observed by [95] and [96] correlating
positively with thiobarbituric acid reactive substances
(TBARS) production, possibly due to lipid peroxidation.
Several studies have addressed Mn’s influence on
AChE activity. Table 4 summarizes the source of the en-
zyme and Mn’s effect on its activity. It is important to
emphasize that Mn effects in biological systems depend
on the routes of exposure, dose, age, period of exposure,
environmental factors and nutritional state [83, 87, 94,
97–100].
ACh binds to two types of cholinergic receptors: the
ionotropic family of nicotinic receptors and the metabo-
tropic family of muscarinic receptors. The nicotinic
acetylcholine receptor (nAChR), at the nerve/muscle
synapse, is one of the best-characterized transmitter-
gated ion channels [101, 102]. The muscarinic receptors
belong to the large superfamily of plasma membrane-
bound G protein coupled receptors (GPCRs) [103]. The
muscarinic receptor family has five known members
designated M1–M5. Mn exposure can affect the binding
of ACh to cholinergic receptors. For example, intranasal
Mn treatment in adult mice down-regulates nicotinic
acetylcholine receptors (nAChR) in the prefrontal cortex
in wild-type (high Fe accumulation) Hfe+/+ and Hfe-
knockout Hfe−/−animals [85]. However, in other studies
no alterations were found in the binding or density of
cholinergic receptors. Chronic administration of MnCl2
(5 mg Mn/kg body weight/day) for 9 weeks, did not
affect the [3H]-quinuclidinyl benzilate binding to mus-
carinic cholinergic receptors in mouse brain [104]. No
changes in the muscarinic receptor density (Bmax) and
the dissociation constant (Kd) of 3H-QNB in the differ-
ent mouse brain regions was observed after daily ip in-
jections of MnCl2 (5 mg Mn/kg) for 9 weeks [105].
Finally, the density of muscarinic receptors in monkeys
remained unchanged after Mn exposure for 26 months at
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Table 3 Transporters and their roles in Mn uptake and efflux
Transporter Localization Role in Mn transport Associated pathologies Reference
Mn importers DMT-1 Highly expressed in the basal ganglia Transports both Mn and Fe and a range
of other cations.
Increased expression of DMT1 has been found in
the SNpc of PD patients. Alterations in DMT1 are
associated with spinal onset amyotrophic lateral
sclerosis, AD onset in males, iron anaemia and
restless legs syndrome
[3, 50]
ZIP8 and ZIP14 Apical surface of various cell types Regulation of Mn homeostasis (in duodenum,
liver, brain, lungs, and kidney) and transfer of
Mn, Fe, Zn, and Cd into the cells
ZIP 8 and −14 facilitate Cd accumulation, a
non-essential toxic metal. MT-null Cd-resistant
cells have been found to exhibit suppressed
expression of both ZIP8 and ZIP14, suggesting
that the down-regulation of both contributes to
the decrease in Cd and Mn uptake
[229–231]
DAT Neurons of SNpc, GP and striatum Reuptake of dopamine into presynaptic vesicles.
Also shown to transport Mn
Patients chronically exposed to Mn display
decreased DAT density and activity. DAT knockout
mice exposed to Mn accumulate significantly less
Mn in the striatum compared to WT
[50, 232]
Ca channels Plasma membrane Voltage-regulated, store-operated Ca2+ channels
as well as ionotropic glutamate receptors also
facilitate Mn uptake into the brain
The number of known ion channel diseases
(channelopathies) has increased dramatically
and include cystic fibrosis, Bartter syndrome
and epilepsy
[233, 234]
Choline transporter Plasma membrane Choline uptake was found to be significantly
inhibited in the presence of Cd and Mn, but
not Cu or Al
Prenatal choline deficiency is associated with
increased choline transporter mRNA expression
in the septum and hippocampus of rats as a
compensatory mechanism for acetylcholine
synthesis
[235, 236]
Citrate transporter Plasma membrane Mn citrate represents the major non-protein-bound
species of Mn to enter the brain at the BBB. The
influx transfer coefficient for Mn citrate was shown
to be greater than that of Mn2 + alone and Tf–Mn3+
Defects in SLC25A1, a mitochondrial citrate
carrier, were identified to cause combined
D-2- and L-2-hydroxyglutaric aciduria
[237, 238]
Tf/TfR Tf in plasma and TfR in the membrane
of neurons, microglia, astrocytes and
the endothelial cells of the BBB
Tf/TfR facilitates Mn3+ influx into the CNS from the
blood stream
Polymorphisms in TfR gene have been
correlated with increased risk of age related
macular degeneration (AMD)
[57, 237, 239, 240]
Mn exporters Fpn Transmembrane, expressed in the
duodenum, liver, spleen, intestine,
endothelial cells of the BBB, neurons,
oligodendrocytes, astrocytes, choroid
plexus and ependymal cells
Increased Fpn expression in HEK293 cells is
associated with decreased intracellular Mn
concentration and attenuated cytotoxicity
Mutations in Fpn cause type IV hemochromatosis,
commonly known as Fpn disease, characterized
by Fe accumulation in reticuloendothelial
macrophages
[50, 62, 63]
SLC30A10 Cell surface-localized. Present in basal
ganglia and liver
Mediates Mn efflux from cells Mutations in SLC30A10 that impair Mn export
induce hypermanganesemia, dystonia, and
polycythemia with a variable degree of hepatic
dysfunction
[22, 23]
SPCA1 Mainly in Golgi membrane of
keratinocytes, liver and brain
Imports Mn2+ from the cytosol to the Golgi lumen Monoallelic mutations in SPCA1 are known to
cause Hailey-Hailey disease, a blistering skin disorder.
Complete loss of function is thought to be unviable
[3, 241]
ATP13A2 or PARK9 Transmembrane, localized on the
membrane of vacuoles and lysosomes
Cation transporting ATPase. Shuttles cations across
lysosomal membrane
ATP13A2 mutations have been associated with
early-onset parkinsonism and Kufor-Rakeb syndrome.
[242–244]
Abbreviations: AD Alzheimer’s disease, ATP13A2 ATPase type 13A2, DAT dopamine transporter, DMT1 divalent metal transporter 1, Fpn ferroportin, MT, metalothionein, SLC solute carrier, SPCA1 secretory pathway Ca2 +














a dose comparable to what workers might inhale in dusty
environments [106]. An overview of the potential effects
of Mn on cholinergic function is depicted in Fig. 1.
Cholinergic signaling is involved in anti-inflammatory
reactions. ACh is the main vagus neurotransmitter
[107–109] and the efferent arm of the inflammatory
reflex, now termed the cholinergic anti-inflammatory
pathway. It is a highly robust mechanism for cytokine
control [110]. The vagus nerve releases ACh when
stimulated (either electrically or pharmacologically),
inhibiting macrophage activation and release of pro-
inflammatory cytokines, e.g. interleukin-6 (IL-6), tumor
necrosis factor alpha (TNF-α), IL-1 and IL-18. One of
the molecular mechanisms for cytokine synthesis inhib-
ition is attributable to ACh [107, 108, 111, 112]. Accord-
ingly, the cholinergic system controls inflammatory
process and is recognized as a possible marker of low-
level systemic inflammation [113–115].
Behavioral consequences of Mn exposure in humans and
experimental models
Mn exposure by inhalation in occupational settings
It is estimated that over one million workers in the USA
perform welding as part of their job. The pipes used in
heating and ventilation systems as well as industrial
process piping often require welding, which is also es-
sential for ductwork, laboratory hoods, tanks, boilers,
and process vessels. Welding produces respirable fumes
that may contain Mn as well as other chemicals, such as
chromium, arsenic, iron and nickel. The level of Mn ex-
posure varies dependent upon the type of welding activ-
ity performed, ranging from 0.01 to 2.0 mg/m3 [116]. In
contrast, the world health organization (WHO) recom-
mends that levels of Mn do not exceed 30 μg/m3. It has
been demonstrated that the use of ventilation systems
reduces these values and could be an effective approach
to minimize Mn exposure [116].
Using rats to model Mn exposure via inhalation, it has
been demonstrated that the inhalation route is more effi-
cient than ingestion at delivering Mn to the brain [117].
Mn is taken up via the olfactory tract and transferred
along olfactory neurons processes through the cribri-
form plate to synaptic junctions with olfactory bulb neu-
rons, thus bypassing the BBB. Once in the brain, Mn
can continue to traverse synapses and be transported
along neuronal tracts to other sites of the brain [118,
119]. Furthermore, the accumulation of Mn in the blood
after intranasal instillation is much greater than via the
oral route because Mn bypasses the biliary excretion
[120]. DMT-1 is important for Mn transport across the ol-
factory epithelium into the brain of rats and can be influ-
enced by Fe status [121]. Other transporters may regulate
Mn uptake from the olfactory epithelium. Candidates are
SLC30A10 or Mn binding proteins [120]. DMT-1 also
plays a role in lung uptake of inhaled Mn [122].
Several studies point to a strong correlation between
occupational Mn exposure and an increased risk of PD
[123]. Parkinsonian symptoms in welders attributed to
Mn exposure have been reported in numerous studies.
A statistically significant difference in the age of PD on-
set between welders (46 years of age) and a control
group (63 years) [124] has been noted. Alpha-synuclein
(α-Syn), the major component of Lewy bodies and the
hallmark of PD, contains metal binding sites, and its ac-
tivity is not yet fully understood. It has been proposed
that α-Syn attenuates Mn-induced DAergic degeneration
in the early stage, but after prolonged exposure, Mn
promotes α-Syn aggregation [125]. In C. elegans, α-Syn
attenuates Mn-induced toxicity in the background of
PD-associated genes [126]. Recently, α-Syn has been
proposed to act as a intracellular Mn store [127].
Because of its paramagnetic properties, Mn accumula-
tion can be visualized using T1-weighted magnetic res-
onance imaging (MRI) [128]. In a study of 193 subjects
exposed to welding activities from the Midwestern USA
Table 4 Effects of Manganese (Mn) exposure on AChE activity in different experimental protocols
Model Tissue Administration route and dose Effect on AChE
activity
Reference
Adult rats Whole Brain Intraperitoneal-acute (10–15 mg/kg) and
chronic (mg/kg)
Increase [100]
Adult rats Cerebellum Oral via by drinking water, 30 days (20 mg/ml) Increase [189]
Rats from 21–74
days
Brain Oral via by food, for 53 days, chronic exposure
(500 mg/kg)
Increase [94]
Adult mice Hypothalamus, pons, cerebellum, striatum,
medulla, cerebral cortex and hippocampus.
Chronic treatment by oral via from conception
to 60 days old
No alterations [98]
0-adult rats Cerebellum and striatum Oral via by drinking water, 60 days (20 mg/ml) Increase [97]
Adult rats Brain Intraperitoneal, 7 days (50 mg/kg) Increase [99]
Adult rats Whole Brain Intraperitoneal-(25 mg/kg) in 4 and 8 doses Decrease [84]
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it was shown that Mn accumulates throughout the basal
ganglia, with a diffused T1 signal as well as elevated
blood Mn levels when compared to age and gender
matched controls. However, it was found that the MRI
data not always correlated with clinical symptomatology
[129, 130]. This may occur because modern occupa-
tional exposure to Mn occurs at much lower levels than
reported in the past, resulting in a less distinguishable
clinical phonotype. Even asymptomatic welder appren-
tices display increased T1 signal in the basal ganglia, but
when evaluated in the Grooved Pegboard (for dexterity
and fine motor control) or the unified PD rating scale
motor subsection 3 (UPDRS3-for parkinsonian signs
such as rest and postural tremor, bradykinesia and gait
disturbance), the subjects performed within the
reference range [131]. Nevertheless important neuro-
pathological alterations have been observed even in the
absence of motor symptoms [129, 132, 133]. It is not
clear from the clinical studies, however, whether Mn
facilitates the development of PD or induces a distinct
Fig. 1 Overview of Manganese (Mn) effects on cholinergic signaling. a Mn promotes an increase in reactive oxygen species production through of
mitochondrial dysfunction. In addition, Mn impairs the synthesis of precursors for acetylcholine neurotransmitter production. b Mn induces up-regulation
of nicotinic and muscarinic receptors. c Mn has a controversial effect on acetylcholinesterase since it is able to increase, reduce or not alter the activity of
this enzyme across diferent models of Mn exposure
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parkinsonian syndrome. Future studies should address this
issue by clearly diagnosing either PD or manganism based
on the known distinctions between the two diseases.
To better understand the significance of MRI findings,
an ex vivo study correlated imaging with neuropathology
in 19 mine workers and 10 race- and sex-matched con-
trols from South Africa (where 80 % of the world’s Mn
reserves are located). It was found an inverse relation-
ship between the T1 intensity indices and neuronal
density in the caudate and putamen, suggesting neuronal
loss. The authors also noted increased microglial cell
density in the basal ganglia. Based on this and their pre-
vious study [133] they propose that the pre-clinical stage
of Mn-induced neurotoxicity is marked by an initial in-
flammatory response that may progress to astrocyte
isruption and neuronal injury [132]. This would be in
agreement with in vitro findings that report a 50 fold
higher accumulation of Mn in astrocytes, which may
alter their neurotrophic actions and contribute no neur-
onal injury [134–137]. Astrocytes are initially affected in
manganism showing changes in the expression of glial
fibrilary acidic protein (GFAP) preceding neuronal death
[138]. Increased GFAP expression is observed in the stri-
atum of rats, which indicates glial activation in response
to Mn [139, 140]. Microglial cells are also affected by Mn
with increased release of proinflammatory cytokines [134]
and may activate astrocytes to release inflammatory medi-
ators such as prostaglandin E2 and nitric oxide [141].
Environmental Mn exposure
Contaminated air or water pose a risk of Mn intoxica-
tion to the general population. Mn exposure from envir-
onmental sources has also been associated with a higher
prevalence of Parkinsonian disturbances [142]. For in-
stance, near foundries, Mn concentrations may reach
200–300 ng/m3, contrasting to normal levels of Mn in
the air that are around 10–30 ng/m3 according to the
WHO. Recently, a study by Bowler et al. (2015) was per-
formed to assess cognitive function in adults environ-
mentally exposed to Mn in Ohio, USA, in two towns
identified as having high levels of air-Mn from industrial
sources. The authors report that non-occupational envir-
onmental Mn exposure appears to be associated with
lower performance on neuropsychological tests measur-
ing a variety of cognitive functions [143].
North America’s longest operating ferromanganese
refinery is located in Marietta, Ohio, USA. To address
the population leading environmental public health
concern, a study was conducted to evaluate children’s
cognitive function. It was found that both high and
low blood and hair levels of Mn could negatively im-
pact children’s IQ, consistent with the notion that Mn
is both a nutrient and a neurotoxicant. Of note, lead
(Pb) and cotinine (a nicotine metabolite) were also
measured in children’s blood, serum or hair since en-
vironmental exposures to toxic chemicals rarely occur
isolated. Pb levels in blood of that study population
were similar to mean blood Pb of children in the
USA and did not influence IQ scores. Cotinine levels
were significantly associated with IQ scores, demon-
strating that secondhand tobacco smoke can nega-
tively impact child cognitive function [144]. Airborne
Mn also detrimentally influenced children’s postural
stability in this population [145]. Mn has been identified
as a developmental neurotoxicant associated with hyper-
activity, lower intellectual function, impaired motor skills
and reduced olfactory function in children [146, 147]. In
animal models, the immature CNS is more susceptible to
Mn neurotoxicity compared to the adult [148] and experi-
mental evidence suggests that exposure to this metal during
development can affect neurological function in adulthood
[139, 140, 149, 150].
The presence of excessive Mn levels in drinking water
has been associated with poorer memory and attention
[14], and hyperactive behavior [151] in school-aged
children. Consumption of water containing elevated Mn
levels had adverse effects on 10-year-old children’s cogni-
tive function [152]. Children exposed to elevated airborne
Mn in an area close to a ferromanganese alloy plant in
Brazil presented lower I.Q., impairment of verbal skills
[153] and lower neuropsychological performance in tests
of executive function of inhibition responses, strategic
visual formation and verbal working memory [154].
Mn and parenteral nutrition
Mn is present in parenteral nutrition formulations both as
an essential element but also as a contaminant, thus pos-
ing as an important source of excessive exposure to Mn.
The content of Mn in TPN varies from 0.18 μmol/d
(0.01 mg/d) to 40 μmol/d (2.2 mg/d) [21]. Toxicity to Mn
has been observed in adults receiving >500 μg/d and in
pediatric patients receiving >40 μg/kg/d. Furthermore,
duration of TPN treatment is associated with increased
blood and brain concentrations of Mn [155–157]. Thus,
current guidelines recommend monitoring patients for
Mn toxicity if they receive TPN longer than 30 days [158].
Parenteral administration bypasses the regulatory mech-
anisms of the gastrointestinal tract. The bioavailability of
Mn in parenteral fluid is 100 %, compared to only 5 % for
enteral dietary Mn. For newborns, the Mn burden derived
from parenteral nutrition can be 100 times greater than
human milk. Of particular importance, the hepatic mecha-
nisms responsible for Mn excretion are not completely de-
veloped in newborns. This factor combined with the high
bioavailability of the metal in TPN increases the risk of
Mn overload. That is also true for patients with hepatic
dysfunction [17, 18, 21, 157].
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Behavioral studies of Mn intoxication
Several reports address the effects of Mn exposure on
behavioral tasks [67, 139, 149, 159–170]. Some of these
effects are described on Table 5. As for ChAT and AChE
activity, it can be observed that the animal model, the
duration of exposure and the administration route are
important variables when studying behavioral parame-
ters. Briefly, the most common tasks analyzed in the ref-
erences below are: Morris water maze task (MWM) an
hippocampal-dependent learning test, including acquisi-
tion of spatial memory and long-term spatial memory
[171]; 8-arm radial maze paradigms to evaluate reference
and working memory performance simultaneously [172];
active avoidance paradigms that utilizes the passive
avoidance and active avoidance test paradigms, which
assay different forms of fear-based conditioned avoid-
ance considered to be an escape response [173]; variable
delayed response (VDR) task where monkeys are trained
to perform cognitive tasks while seated in a restraining
chair. VDR analyzes both attentional and spatial working
memory components [165]; self-ordered spatial search
(SOSS) task and Five Choice serial reaction time (5-
CSRT) task. The SOSS task requires animals to touch
identical squares located in different spatial locations in
a self-ordered sequence without returning to a previ-
ously touched square. The 5-choice serial reaction time
(5-CSRT) task is a widely used test to measure multiple
aspects of cognition including attention, impulsivity and
perseveration [167]; The object recognition task utilizes
the exploration time spent in the new and familiar ob-
jects are used as parameters to asses memory and finally
the social recognition test to observe short-term mem-
ory impairments [139].
In C. elegans, Mn exposure has been shown to result
specifically in DAergic neurodegeneration [174]. In C.
elegans DAergic neurons are considered mechanosen-
sory and any condition impairing DA signaling will
affect the ability to sense or respond to changes in its
environment. DA signaling plays an important role in
learning and regulation of locomotor behavior, including
basal slowing response, ethanol preference, area-restricted
searching, habituation task/tap withdrawal response, egg
laying, dauer movement, pharyngeal pumping and thrash-
ing behaviors [175, 176]. Among these behaviors, basal
slowing response is DA-specific, and other behaviors are
usually controlled by DA along with other neurotransmit-
ters, such as serotonin, glutamate or GABA, etc. To date,
basal slowing response and dauer movement have been
studied with Mn exposure [175, 177, 178]. Levya-Illades,
Chen et al. (2014), have shown that Mn exposure resulted
in decreased basal slowing response, while expression of
Mn exporter SLC30A10 exclusively in DAergic neurons
rescued this behavioral defect together with decreased
DAergic neurodegeneration [67]. In WT dauer worms,
the locomotion was increased in the presence of Mn, indi-
cating DA signaling is damaged by Mn exposure [176].
Similarly, the movement in djr-1.2 (homolog of mamma-
lian DJ-1) worms was increased, indicating that loss of DJ-
1 function resulted in abnormal DAergic neurons.
Neuroprotective strategies against Mn
Mn-induced neurotoxicity may present in different animal
models with distinct damage, depending on time of expos-
ure, dose and route of exposure [179, 180]. In this regard,
different therapeutic approaches have been studied in
different models. Originally, Mn-induced parkinsonism
patients were treated with levodopa, however they were
unresponsive to the treatment [181, 182] possibly due to
the relatively intact nigrostriatal pathway in the latter
phase of the disorder [9]. Hence, other treatments have
been tested. We will briefly discuss in vitro and in vivo in-
vestigations on the properties of endogenous antioxidants
(for instance, vitamin E), plant extracts (complex mixtures
containing polyphenols and non-characterized compo-
nents), Fe chelating agents, precursors of glutathione
(GSH), and synthetic compounds that can experimentally
afford protection against Mn-induced neurotoxicity.
Vitamin E and GSH
Vitamin E and trolox (a hydrophilic analog of vitamin E)
have been reported to protect the CNS of rodents and
cultured cells from the toxic effects of Mn [183–185].
I.p. exposure of lactating rats to Mn caused striatal and
hippocampal oxidative stress and motor impairments,
which were prevented by trolox co-administration [183].
GSH and N-Acetylcysteine (NAC), a precursor of GSH,
can also decrease the toxicity of Mn in vitro [186]; how-
ever, the protective mechanism involved in NAC and
GSH has yet to be fully studied. It is likely that these
compounds serve as indirect antioxidants since GSH is a
substrate of glutathione peroxidase (GPx) enzymes.
Plant extracts
Plant extracts have been demonstrated to confer protec-
tion against Mn neurotoxicity after in vitro [81] and in
vivo exposure in mice [187]. Acai (Euterpe oleracea)meth-
anolic extract protected astrocytes from Mn-induced oxi-
dative stress. The protective effects may be associated
with the antioxidant and anti-inflammatory effects of its
anthocyanin components [81]. Similarly, crude aqueous
extracts of Melissa officinalis blunted the Mn-induced
striatal and hippocampal lipid peroxidation [187]. Purified
flavonoids, such as, silymarin (obtained from Silybum
marianum, a plant with hepatoprotecive properties) pro-
tected neuroblastoma cells [188] and prevented Mn-
induced oxidative stress in brain, liver, and kidney of rats
[189–191]. Lycopene has also been reported to decrease
the neurotoxicity of Mn in rats [192].
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Table 5 Effects of Manganese (Mn) on different behavioral tasks
Experimental model Treatment Behavioral task Results Reference
Male Sprague-Dawley rats Neonate rats were orally exposed to MnCl2
(0, 25, 50 mg/kg/day) between PND1-21





One group was treated with 14.84
(low dose group), and another one with 59.36
(high dose group), mg/kg Mn given by gavage,
5 days a week for 10 weeks.
8-arm radial maze task MnCl2 treated groups showed, compared to
control animals, a decrease in the average
memory performance
[170]
Male Wistar rats Single oral doses of MnCl2 (50 mg/kg) or




Single dose induced decline of the memory
acquisition of an avoidance reaction in response
to unconditioned and conditioned stimuli.
Chronic manganese poisoning also led to
significant impairment of learning processes
[168]
C. elegans 1 h Mn (10 or 25 mM) exposure on L1
larval stage
Basal slowing response Mn-exposed worms had an impaired basal
slowing response, indicating DAergic damage.
This was reversed by SLC30A10 (a cell
surface-localized Mn efflux transporter)
expression in DAergic neurons
[67]
C. elegans 30 min Mn (50 mM) exposure on L1 larval stage Dauer movement In WT dauer worms, the locomotion was
increased in the presence of Mn, indicating
DA signaling impairment
[161]
Male and female Sprague-Dawley rats Pregnant females treated with Mn (2 mg/ml)
in drinking water from the first day of pregnancy
until PND20.
MWM PND 21–25: Mn-exposed females displayed
memory deficits in the probe trial
PND 56–60: Mn-exposed males performed
significantly worse in the acquisition trial.
Females exposed to Mn displayed deficits in
learning and memory
[159]
Three-month-old male Wistar rats Intranasal 2-week-long MnCl2 (0.8 mg/kg
body weight)
MWM Spatial memory deficits [160]
Male Sprague-Dawley
rats
Intraperitoneal injection of MnCl2 15 mg/kg for
8, 12 or 18 weeks
MWM Escaping latency and swimming distance of rats
in the model groups increased, suggesting spatial
learning and memory impairment
[162]
Male Sprague Dawley rats Intraperitoneal injections of 0, 5, 10 and 20 mg/kg
MnCl2 once daily, 5 days/ week for 18 weeks.
MWM Mn impaired learning and memory as follow:
In 6 weeks at dose 20 mg/kg. In 12 weeks at
doses 10 and 20 mg/kg. In 18 weeks at doses 5,
10 and 20 mg/kg
[163]
Male Sprague-Dawley
rats (6 weeks of age)
Intraperitoneal injections 15 mg/kg MnCl2 daily for
8 weeks.
MWM The escape latency in the Morris water maze test
was significantly longer in the rats injected with




Intraperitoneal injections (5, 10, 20 mg/kg MnSO4)
5 days a week for 24 weeks
MWM Mn exposure decreased the spatial learning ability
in a dose- and time- dependent manner
[169]
Male Wistar rats Exposed intraperitoneally to MnCl2 at doses 5, 10
or 20 mg/kg/day from PND 8–12
Object and social recognition tasks PND 60–65: Rats exposed to the highest Mn dose
failed to recognize a familiar object when replaced
by a novel object as well as to recognize a familiar
















Table 5 Effects of Manganese (Mn) on different behavioral tasks (Continued)
Adult male M. fascicularis
macaques, 5 to 6 years old
Mn was administered as MnSO4 for 15 mg/kg/week
for 5 weeks and then 20 mg /kg/week for the
remainder of the study period (12 months)
SOSS and
5-CSRT tasks
Deficits in performance of the SOSS task began to
appear by the fourth month of Mn exposure but
only became consistently significantly impaired
beginning at the ninth month of Mn exposure.
Performance on the 5-CSRT became significantly
affected by the third month of Mn exposure
[167]
Adult male M. fascicularis monkeys
with 5 to 6 years old
MnSO4 at doses 10–15 mg/kg/week over an
exposure period
lasting 272 ± 17 days
Variable delayed
response task
Animals developed subtle deficits in spatial
working memory and had modest decreases
in spontaneous activity and manual dexterity
[166]
Adult male M. fascicularis macaques,
5 to 6 years old
MnSO4 at doses 15–20 mg/kg/week over an
exposure period lasting 227.5 ± 17.3 days
Variable delayed response task Animals developed mild deficits in spatial
working memory, more significant deficits in
non-spatial working memory and no deficits
in reference memory
[165]















Because of the chemical similarities between Mn and Fe, it
is possible that the neurotoxic effects of Mn might be asso-
ciated with competition with Fe for “non-redox” domains in
proteins [193]. Consequently, compounds with Fe chelating
properties or those interfering with the Fenton’s reaction,
such as polyphenol compounds, can be of potential
pharmacological importance in the treatment of Mn toxicity
[194–196]. Indeed, the treatment with a calcium disodium
salt of the chelator EDTA (CaNa2EDTA) reduced Mn-
induced DA autooxidation in vitro [197], enhanced urinary
excretion of Mn in humans [198] and reduced Mn levels in
the brain and liver of Mn-exposed rats [199]. However, there
is still controversy regarding the amelioration provided by
this chelating therapy [200, 201].
Synthetic compounds
Synthetic molecules have also been reported to reduce Mn
toxicity. For instance, several organochalcogens (i.e. organo-
compounds containing selenium or tellurium atoms bound
to carbon) have been reported to possess antioxidant and
anti-inflammatory properties [202]. The protective effects of
organoselenide and telluride compounds against Mn-
induced neurotoxicity, including ebselen, have been reported
[184]. One proposed mechanism might be related to a direct
scavenger activity against ROS produced by Mn as most of
these compounds have thiol-peroxidase activity catalyzed by
glutathione-peroxidase isoforms [202]. Using the comple-
mentary animal model C. elegans, it was shown that these
compounds could modulate the transcription factor DAF-
16 (FOXO in mammals), increasing its translocation to the
nucleus. In turn, the expression of antioxidant enzymes such
as superoxide dismutase increased, thus protecting the
worms from Mn-induced toxicity [203, 204]. An additional
proposed mechanism is the anti-inflammatory action of
some of these compounds, e.g. ebselen. Consequently, in
addition to counteracting free radicals and modulating gene
expression, ebselen and related compounds could decrease
Mn toxicity via anti-inflammatory properties. Of note, anti-
inflammatory agents have been reported to decrease Mn
neurotoxicity in vitro and after in vivo exposure. For
instance, Santos et al. (2013) demonstrated in vitro that
5- aminosalicylic acid (5-ASA) and para-aminosalicylic acid
(4-PAS) increased mitochondrial and cell viability following
Mn exposure [205]. Ibuprofen, a nonsteroidal anti-
inflammatory drug, protected striatal neurons from den-
dritic atrophy and spine loss in rats treated for 2 weeks with
the drug prior to Mn exposure [184].
The indirect pro-oxidative effects of Mn have been
linked to disruption of synaptic glutamate homeostasis
by interfering with glutamate uptake in astrocytes [206].
The increase in extracellular glutamate can cause excito-
toxicity, which is associated with oxidative stress in
neurons [206]. Furthermore, Mn decreases astrocytic
glutamate uptake and expression of the astrocytic glutam-
ate/aspartate transporter (GLAST) via disruption of intra-
cellular signaling [207]. Of potential clinical significance,
estrogen and tamoxifen have been reported to increase
the expression of glutamate transporters (both GLAST
and GLT-1) in astrocytes, potentially decreasing Mn tox-
icity [77, 207–210]. Raloxifene, which is a selective estro-
gen receptor modulator, also attenuates the reduction of
GLT-1 and GLAST expression and the glutamate uptake
induced by Mn in astrocytes [211], thus confirming how
promising this class of molecules might be.
Finally, preventing or reducing Mn exposure is essential.
For instance, methodologies by which welding fumes gener-
ation rate and/or welding practices can be modified to re-
duce toxic workplace exposures should be sought. In this
context, a recent study of Sriram et al. (2015) demonstrated
that rats exposed by whole body inhalation to an altered
welding process (parameters: voltage, current and shielding
gas) showed absence of neurotoxicity when compared to the
rats exposed to regular welding process [11]. Reducing Mn
levels in infant milk formulas and on parenteral nutrition
should also be a strategy as safety policy.
Conclusions
The interest in researching Mn toxicity has grown in the
past few decades. Recent clinical studies in populations
exposed to the metal via occupational or environmental
sources demonstrate Mn accumulation in the brain with
T1-weighted MRI. Evidence for cognitive and motor im-
pairment, especially in children has also been presented.
Furthermore, it is evidenced by the work mentioned
above that the use of rodent and other complimentary
models is an important tool for the study of mechanisms
of Mn toxicity, focusing on Mn transport, metal homeo-
stasis, behavioral outcomes and neuroprotective strat-
egies. Animal models facilitate the use of different routes
of exposure to Mn, as well as the use of different chemical
forms of Mn, that can mimic environmental or occupa-
tional exposure. C. elegans is also an excellent tool for
genetic analysis and manipulations. The availability of mu-
tants and green fluorescent protein (GFP)-tagging makes
it easy to explore a wide range of chemicals and their
effects. Several effects in response to exposure to metals,
especially those involving gene expression and behavior
have been reported using the nematode as a model.
One of the particularities of Mn mechanism of action
is that it accumulates preferentially in the basal ganglia
and targets DAergic neurons. However, various studies
show that Mn may also affect other neurotransmitter
systems. In this context, it is important to emphasize
that to better understand Mn neurotoxic effects a cross
talk between DAergic and cholinergic systems seems to
be important, specially when regarding the brain regions
related with PD and manganism, such as striatum, where
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cholinergic interneurons are present. Moreover, the
neurotransmission at the neuromuscular junction and
how it can lead to the motor impairment observed in
manganism is an area that needs further exploration.
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